Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic ...

A study shows that combining dual immunotherapy with chemotherapy improves outcomes for metastatic non-squamous NSCLC patients with STK11 and KEAP1 mutations. Learn more ...

Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of ...

The trial entitled “Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway- Deficient NSCLC” is a Phase I/II trial where Phase I is a dose escalation study establishing the ...

Individuals can make various changes to their lifestyles to help reduce their chances of developing certain types of cancer, ...

harboring specific mutations in the STK11 ... Common Breast Cancer Treatments May Speed Aging Process Oct. 7, 2024 — Markers of cellular aging -- such as DNA damage response, cellular senescence ...

BerGenBio announces safety data from phase 1b portion of BGBC016 study in first-line NSCLC: Bergen, Norway Tuesday, October 8, 2024, 15:00 Hrs [IST] BerGenBio ASA, a clinical-stag ...

Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more ...

The trial entitled “Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway- Deficient NSCLC” is a Phase I/II trial where Phase I is a dose escalation study ...